The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice.
Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence.
Specifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after
1. curative-intended surgery and 2. adjuvant chemotherapy.
FRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project
Pancreatic ductal adenocarcinoma, according to the assessment of the MDT.
Age 18 years or older.
Scheduled for curative intent surgical resection.
Hereditary pancreatic cancer.
Verified distant metastases.
Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and/or otherwise considered by the Investigator to be unlikely to complete the study.
Other cancers (excluding prior pancreatic cancer or skin cancer other than melanoma) within 3 years from eligibility screening.